Abstract
Summary
The global sarcopenia treatment market is expected to reach USD 4,043,993.94 thousand by 2030 from USD 2,770,500.00 thousand in 2022, growing at a CAGR of 4.9% in the forecast period of 2023 to 2030.
Market Segmentation
Global Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route Of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country ( U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, and Rest Of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Taiwan, And Rest Of Asia-Pacific, Brazil, Argentina, and Rest Of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Oman, Qatar, Bahrain, and Rest Of Middle East and Africa) - Industry Trends and Forecast to 2030
Overview of Global Sarcopenia Treatment Market Dynamics
Driver
• Rising prevalence of sarcopenia
Restraint
• Lack of standardized diagnosis
Opportunity
• Strategic initiatives by key market players
Market Players
Some of the key market players operating in the global sarcopenia treatment market are listed below:
• Abbott,
• Nestlé Health Science (A subsidiary of Nestlé S.A.),
• Novartis AG
• Sanofi
• Haleon Group of Companies
• BASF SE
• DSM
• Fermenta Biotech Limited
• AstaReal Co., Ltd.
• Metagenics
• BioThrive Sciences.
• Wellona Pharma
• The Vitamin Company India
• Biogen SA
• Healing Pharma India Pvt. Ltd
• Others
Table of Contents
1 INTRODUCTION 50
1.1 OBJECTIVES OF THE STUDY 50
1.2 MARKET DEFINITION 50
1.3 OVERVIEW OF THE GLOBAL SARCOPENIA TREATMENT MARKET 50
1.4 CURRENCY AND PRICING 52
1.5 LIMITATIONS 52
1.6 MARKETS COVERED 52
2 MARKET SEGMENTATION 55
2.1 MARKETS COVERED 55
2.2 GEOGRAPHICAL SCOPE 56
2.3 YEARS CONSIDERED FOR THE STUDY 57
2.4 DBMR TRIPOD DATA VALIDATION MODEL 58
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 61
2.6 MULTIVARIATE MODELLING 62
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 62
2.8 MARKET END USER COVERAGE GRID 63
2.9 DBMR MARKET POSITION GRID 64
2.10 VENDOR SHARE ANALYSIS 66
2.11 SECONDARY SOURCES 67
2.12 ASSUMPTIONS 67
3 EXECUTIVE SUMMARY 68
4 PREMIUM INSIGHTS 71
4.1 PESTEL ANALYSIS 72
4.2 PORTER’S FIVE FORCES MODEL 73
4.3 CURRENT STATUS OF EMERGING DRUGS FOR SARCOPENIA TREATMENT 74
5 GLOBAL SARCOPENIA TREATMENT MARKET: REGULATIONS 75
5.1 REGULATIONS IN U.S 75
5.2 REGULATIONS IN EUROPE 75
5.3 REGULATIONS IN AUSTRALIA 76
5.4 REGULATIONS IN SOUTH AFRICA 76
6 MARKET OVERVIEW 77
6.1 DRIVERS 79
6.1.1 RISING PREVALENCE OF SARCOPENIA 79
6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 79
6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 80
6.2 RESTRAINTS 81
6.2.1 LACK OF STANDARDIZED DIAGNOSIS 81
6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 81
6.3 OPPORTUNITIES 82
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 82
6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 82
6.4 CHALLENGES 83
6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 83
6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 84
7 GLOBAL SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 85
7.1 OVERVIEW 86
7.2 VITAMIN/DIETARY SUPPLEMENTS 89
7.2.1 VITAMIN SUPPLEMENTS 90
7.2.2 PROTEIN SUPPLEMENTS 90
7.2.3 FATTY ACID SUPPLEMENTS 90
7.2.4 CREATINE 90
7.2.5 WHEY PROTEINS 90
7.2.6 L-CARNITINE 90
7.2.7 SOY 90
7.2.8 BETA-ALANINE 90
7.2.9 OSTARINE 90
7.2.10 COLLAGEN PEPTIDES 90
7.2.11 LIGANDROL 91
7.2.12 BRANCH-CHAIN AMINO ACIDS 91
7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 91
7.2.14 MEDIUM CHAIN TRIGLYCERIDES 91
7.2.15 OTHERS 91
7.3 MEDICATIONS 91
7.3.1 OFF LABEL DRUGS 92
7.3.2 EMERGING DRUGS 92
- 7.3.2.1 ACE INHIBITORS 92
- 7.3.2.2 APPETITE STIMULANTS 92
- 7.3.2.3 ORAL ANTIDIABETIC DRUGS 92
- 7.3.2.4 OTHERS 93
7.4 OTHERS 93
8 GLOBAL SARCOPENIA TREATMENT MARKET, BY TYPE 94
8.1 OVERVIEW 95
8.2 PRIMARY SARCOPENIA 98
8.2.1 VITAMIN/DIETARY SUPPLEMENTS 98
8.2.2 MEDICATIONS 98
8.2.3 OTHERS 98
8.3 SECONDARY SARCOPENIA 99
8.3.1 VITAMIN/DIETARY SUPPLEMENTS 99
8.3.2 MEDICATIONS 99
8.3.3 OTHERS 99
9 GLOBAL SARCOPENIA TREATMENT MARKET, BY STAGES 100
9.1 OVERVIEW 101
9.2 PRE-SARCOPENIA 104
9.3 SARCOPENIA 104
9.4 SEVERE SARCOPENIA 105
10 GLOBAL SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 106
10.1 OVERVIEW 107
10.2 ORAL 110
10.3 INJECTABLES 110
10.4 OTHERS 111
11 GLOBAL SARCOPENIA TREATMENT MARKET, BY GENDER 112
11.1 OVERVIEW 113
11.2 MALE 116
11.3 FEMALE 116
12 GLOBAL SARCOPENIA TREATMENT MARKET, BY END USER 117
12.1 OVERVIEW 118
12.2 HOSPITALS 121
12.2.1 PUBLIC 121
12.2.2 PRIVATE 121
12.3 SPECIALTY CLINICS 122
12.4 HOME HEALTHCARE 122
12.5 OTHERS 123
13 GLOBAL SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 124
13.1 OVERVIEW 125
13.2 DIRECT TENDER 128
13.3 RETAIL SALES 128
13.3.1 HOSPITAL PHARMACIES 129
13.3.2 ONLINE PHARMACIES 129
13.3.3 OTHERS 129
13.4 OTHERS 129
14 GLOBAL SARCOPENIA TREATMENT MARKET, BY REGION 130
14.1 OVERVIEW 131
14.2 NORTH AMERICA 135
14.2.1 U.S 141
14.2.2 CANADA 147
14.2.3 MEXICO 153
14.3 EUROPE 159
14.3.1 GERMANY 166
14.3.2 FRANCE 172
14.3.3 U.K 178
14.3.4 ITALY 184
14.3.5 SPAIN 190
14.3.6 RUSSIA 196
14.3.7 TURKEY 202
14.3.8 BELGIUM 208
14.3.9 NETHERLANDS 214
14.3.10 SWITZERLAND 220
14.3.11 DENMARK 226
14.3.12 NORWAY 232
14.3.13 SWEDEN 238
14.3.14 POLAND 244
14.3.15 FINLAND 251
14.3.16 REST OF EUROPE 257
14.4 ASIA-PACIFIC 258
14.4.1 JAPAN 265
14.4.2 CHINA 272
14.4.3 SOUTH KOREA 278
14.4.4 INDIA 284
14.4.5 AUSTRALIA 290
14.4.6 SINGAPORE 296
14.4.7 THAILAND 302
14.4.8 MALAYSIA 308
14.4.9 INDONESIA 314
14.4.10 PHILIPPINES 320
14.4.11 VIETNAM 326
14.4.12 NEW ZEALAND 332
14.4.13 TAIWAN 338
14.4.14 REST OF ASIA-PACIFIC 344
14.5 SOUTH AMERICA 345
14.5.1 BRAZIL 351
14.5.2 ARGENTINA 357
14.5.3 REST OF SOUTH AMERICA 363
14.6 MIDDLE EAST AND AFRICA 364
14.6.1 SOUTH AFRICA 371
14.6.2 SAUDI ARABIA 377
14.6.3 U.A.E 383
14.6.4 EGYPT 390
14.6.5 ISRAEL 396
14.6.6 OMAN 403
14.6.7 QATAR 410
14.6.8 BAHRAIN 416
14.6.9 REST OF MIDDLE EAST AND AFRICA 423
15 GLOBAL SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE 424
15.1 COMPANY SHARE ANALYSIS: GLOBAL 424
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 425
15.3 COMPANY SHARE ANALYSIS: EUROPE 426
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 427
16 SWOT ANALYSIS 428
17 COMPANY PROFILE 429
17.1 ABBOTT 429
17.1.1 COMPANY SNAPSHOT 429
17.1.2 REVENUE ANALYSIS 429
17.1.3 COMPANY SHARE ANALYSIS 430
17.1.4 PRODUCT PORTFOLIO 430
17.1.5 RECENT DEVELOPMENT 430
17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.) 431
17.2.1 COMPANY SNAPSHOT 431
17.2.2 REVENUE ANALYSIS 431
17.2.3 COMPANY SHARE ANALYSIS 432
17.2.4 PRODUCT PORTFOLIO 432
17.2.5 RECENT DEVELOPMENT 432
17.3 NOVARTIS AG 433
17.3.1 COMPANY SNAPSHOT 433
17.3.2 REVENUE ANALYSIS 433
17.3.3 COMPANY SHARE ANALYSIS 434
17.3.4 PRODUCT PORTFOLIO 434
17.3.5 PIPELINE PORTFOLIO 434
17.3.6 RECENT DEVELOPMENT 434
17.4 SANOFI 435
17.4.1 COMPANY SNAPSHOT 435
17.4.2 REVENUE ANALYSIS 435
17.4.3 COMPANY SHARE ANALYSIS 436
17.4.4 PRODUCT PORTFOLIO 436
17.4.5 RECENT DEVELOPMENT 436
17.5 HALEON GROUP OF COMPANIES 437
17.5.1 COMPANY SNAPSHOT 437
17.5.2 REVENUE ANALYSIS 437
17.5.3 COMPANY SHARE ANALYSIS 438
17.5.4 PRODUCT PORTFOLIO 438
17.5.5 RECENT DEVELOPMENT 438
17.6 ASTAREAL CO., LTD 439
17.6.1 COMPANY SNAPSHOT 439
17.6.2 PRODUCT PORTFOLIO 439
17.6.3 RECENT DEVELOPMENT 439
17.7 BASF SE 440
17.7.1 COMPANY SNAPSHOT 440
17.7.2 REVENUE ANALYSIS 440
17.7.3 PRODUCT PORTFOLIO 441
17.7.4 RECENT DEVELOPMENT 441
17.8 BIOGEN SA 442
17.8.1 COMPANY SNAPSHOT 442
17.8.2 PRODUCT PORTFOLIO 442
17.8.3 RECENT DEVELOPMENT 442
17.9 BIOTHRIVE SCIENCES 443
17.9.1 COMPANY SNAPSHOT 443
17.9.2 PRODUCT PORTFOLIO 443
17.9.3 RECENT DEVELOPMENT 443
17.10 DSM 444
17.10.1 COMPANY SNAPSHOT 444
17.10.2 REVENUE ANALYSIS 444
17.10.3 PRODUCT PORTFOLIO 445
17.10.4 RECENT DEVELOPMENT 445
17.11 FERMENTA BIOTECH LIMITED 446
17.11.1 COMPANY SNAPSHOT 446
17.11.2 REVENUE ANALYSIS 446
17.11.3 PRODUCT PORTFOLIO 447
17.11.4 RECENT DEVELOPMENT 447
17.12 HEALING PHARMA INDIA PVT. LTD 448
17.12.1 COMPANY SNAPSHOT 448
17.12.2 PRODUCT PORTFOLIO 448
17.12.3 RECENT DEVELOPMENT 448
17.13 METAGENICS 449
17.13.1 COMPANY SNAPSHOT 449
17.13.2 PRODUCT PORTFOLIO 449
17.13.3 RECENT DEVELOPMENT 449
17.14 THE VITAMIN COMPANY INDIA 450
17.14.1 COMPANY SNAPSHOT 450
17.14.2 PRODUCT PORTFOLIO 450
17.14.3 RECENT DEVELOPMENT 450
17.15 WELLONA PHARMA 451
17.15.1 COMPANY SNAPSHOT 451
17.15.2 PRODUCT PORTFOLIO 451
17.15.3 RECENT DEVELOPMENT 451
17.16 ARMGO PHARMA, INC 452
17.16.1 COMPANY SNAPSHOT 452
17.16.2 PIPELINE PORTFOLIO 452
17.16.3 RECENT DEVELOPMENT 452
17.17 BIOPHYTIS 453
17.17.1 COMPANY SNAPSHOT 453
17.17.2 PIPELINE PORTFOLIO 453
17.17.3 RECENT DEVELOPMENT 453
17.18 DYSTROGEN THERAPEUTICS CORP 454
17.18.1 COMPANY SNAPSHOT 454
17.18.2 PIPELINE PORTFOLIO 454
17.18.3 RECENT DEVELOPMENT 454
17.19 IMMUNOFORGE INC 455
17.19.1 COMPANY SNAPSHOT 455
17.19.2 PIPELINE PORTFOLIO 455
17.19.3 RECENT DEVELOPMENT 455
17.20 MYMD PHARMACEUTICALS 456
17.20.1 COMPANY SNAPSHOT 456
17.20.2 PIPELINE PORTFOLIO 456
17.20.3 RECENT DEVELOPMENT 456
17.21 NMD PHARMA A/S 457
17.21.1 COMPANY SNAPSHOT 457
17.21.2 PIPELINE PORTFOLIO 457
17.21.3 RECENT DEVELOPMENT 457
17.22 ONCOCROSS CO., LTD 458
17.22.1 COMPANY SNAPSHOT 458
17.22.2 PIPELINE PORTFOLIO 458
17.22.3 RECENT DEVELOPMENT 458
17.23 OPKO HEALTH, INC 459
17.23.1 COMPANY SNAPSHOT 459
17.23.2 REVENUE ANALYSIS 459
17.23.3 PIPELINE PORTFOLIO 460
17.23.4 RECENT DEVELOPMENT 460
17.24 REGENERON PHARMACEUTICALS INC 461
17.24.1 COMPANY SNAPSHOT 461
17.24.2 REVENUE ANALYSIS 461
17.24.3 PIPELINE PORTFOLIO 462
17.24.4 RECENT DEVELOPMENT 462
17.25 REJUVENATE BIOMED NV 463
17.25.1 COMPANY SNAPSHOT 463
17.25.2 PIPELINE PORTFOLIO 463
17.25.3 RECENT DEVELOPMENT 463
18 QUESTIONNAIRE 464
19 RELATED REPORTS 468